Q2 2024 Earnings Summary
- Strong Financial Performance and Margin Improvement: LDOS reported a record adjusted EBITDA margin of 13.5% in Q2 2024, with adjusted EBITDA up 33% year-over-year . The Health and Civil segment's non-GAAP operating income margin increased to 24.9%, up from 14% a year ago, driven by higher volumes in managed health services and incentive fee awards . The Defense Systems segment achieved double-digit profitability, marking a significant improvement and signaling future growth potential .
- Robust Pipeline and Growth Opportunities: The company has a pipeline of nearly $70 billion in the next 12 months and a qualified pipeline approaching $200 billion, positioning it well for future contract awards . LDOS has submitted $15 billion in bids and has $26 billion awaiting customer decisions , indicating strong future revenue opportunities.
- Strategic Focus on Technological Innovation and Talent Acquisition: LDOS is investing in areas like trusted mission AI, cybersecurity, and quantum technologies to drive future growth . The company is enhancing its business capture performance by hiring dozens of key account managers and frontline growth leaders with deep mission and customer expertise, improving its ability to win new business .
- Leidos faced significant write-downs of $39 million in their U.K. business, primarily on two fixed-price mission software development programs due to changing requirements and schedule slippages, suppressing non-GAAP operating income margin in their Commercial and International segment to 0.7% in the quarter.
- The National Security and Digital segment grew revenues by only 1% year-over-year, and the company anticipates lower margins in the second half, indicating ongoing challenges in accelerating growth and maintaining profitability in this core segment.
- The company acknowledges that certain parts of their portfolio will not receive differential investment and may not contribute significantly to growth, suggesting potential stagnation or underperformance in those areas.
-
VBA Exam Business Outlook
Q: Will health margins decline next year due to VBA contract?
A: Management is uncertain about margins for the medical exam business next year because they are awaiting the RFP for the VBA contract recompete. While an extension is possible, they do not expect a decrease in profitability and are preparing for various scenarios. -
Portfolio Strategy
Q: Update on portfolio pruning initiatives?
A: Management is halfway through building their business strategy and focuses on doubling down on core strengths rather than portfolio pruning. They are investing in areas for future growth but currently see no parts of the business that don't belong in Leidos. -
National Security Segment Margins
Q: What's causing lower margins in national security in H2?
A: Margins were strong in the first half, but management expects them to normalize due to milestone timing and special project work. They emphasize there's no fundamental issue and see upside over time through investments in repeatable models. -
Upcoming Recompetes and Pipeline
Q: Any significant recompetes or new business to watch?
A: Upcoming recompetes include the VBA exam business, hypersonics contracts, TSA logistics support, and the DHMSM contract in 2025. The pipeline is strong with $26 billion awaiting decisions and nearly $70 billion expected in the next 12 months. -
Commercial & International Write-down
Q: Explain the C&I write-down and margin outlook?
A: The C&I segment had a write-down due to two fixed-price contracts in the UK affected by changing requirements and schedule slippage. Management is confident in the second-half outlook and highlights strong performance in the commercial energy business. -
Book-to-Bill Expectations
Q: Should we expect book-to-bill to pick up in H2?
A: Management is committed to a book-to-bill ratio slightly above 1 for 2024, with potential to exceed it depending on contract wins. They emphasize focusing on building quality backlog over time. -
Share Buybacks and Capital Return
Q: Any changes to capital return plans or buyback size?
A: Management is committed to repurchasing $500 million of shares this year and may revisit the amount depending on cash flow. They emphasize prudent capital allocation in a shareholder-friendly manner. -
Cash Flow Outlook
Q: Any factors affecting cash flow in H2?
A: Management doesn't foresee major uses of working capital and expects strong performance in Q3 and Q4, which are usually the strongest cash quarters. They remain focused on converting earnings into cash. -
Margin Guidance Explanation
Q: Why will margins be lower in H2 versus H1?
A: The first half benefited from higher margins, including two quarters' worth of incentives recognized in Q2. Management expects margins to normalize due to anticipated lower activity levels in the VBA exam business and continued investments. -
Counter-UAS Business
Q: Thoughts on the counter-UAS business strategy?
A: Management is evaluating their capabilities in counter-UAS, including technologies in Dynetics and the Leidos Innovation Center. They are exploring investments to help customers address this challenge.
Research analysts covering Leidos Holdings.